Neurovan (Pregabalin)

Therapeutic Group : NSAID & Analgesic

Presentation:

Neurovan-25 Capsule: Each capsule contains Pregabalin INN 25 mg.
Neurovan-50 Capsule: Each capsule contains Pregabalin INN 50 mg.
Neurovan-75 Capsule: Each capsule contains Pregabalin INN 75 mg.

Indications:

Peripheral and central neuropathic pain as adjunctive therapy for partial seizures with or without secondary generalization,

Generalised anxiety disorder

Fibromyalgia.

Dosage & Administration:

Neuropathic pain: Adult over 18 years: Initially 150 mg daily in 2-3 divided doses, increased if necessary after 3-7 days to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses. Epilepsy: Adult over 18 years: Initially 25 mg twice daily. Increased at 7-day intervals in steps of 50 mg daily to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses. Generalised anxiety disorder: Adult over 18 years: Initially 150 mg daily in 2-3 divided doses, increased if necessary at 7-day intervals in steps of 150 mg daily; max. 600 mg daily in 2-3 divided doses. Fibromyalgia: The recommended dose of Pregabalin is 300-450 mg/day. Dosing should begin at 75 mg twice daily and may be increased to 150 mg two times daily within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg twice daily.

Contrainidications:

Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin.

Side effects:

Dry mouth, constipation, nausea, vomiting, flatulence, dizziness, drowsiness etc. may occur. Drug interactions: Since Pregabalin is predomitantly excreted unchanged in the urine, undergoes negligible metabolism in humans, it does not inhibit drug metabolism.

Use in special groups:

Use in pregnancy: Pregabalin is a pregnancy category C drug. It should be used during pregnancy where there are no alternatives and benefits outweigh risk.

Use in nursing mother: There are no data on the excretion of Pregabalin into human milk. Because of the potential for tumorogenicity shown for Pregabalin in animal studies, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Use in children & adolescents: The safety and effectiveness of Pregabalin have not been established in patients below the age of 18 years.

Use in elderly (Over 65 years of age): No dosage adjustment is necessary in elderly patients. Overdose: In overdoses up to 15 g, no unexpected adverse effects were reported.

Packing:

Neurovan-25 Capsule: Each box contains 30’s Capsules in Alu-Alu blister pack.
Neurovan-50 Capsule: Each box contains 30’s Capsules in Alu-Alu blister pack.
Neurovan-75 Capsule: Each box contains 30’s Capsules in blister pack.